GKOS · GLAUKOS Corp
$184.53
-4.92 (-2.60%)
At close · Aug 14
Market Cap
$10.88B
Shares
58.98M
GLAUKOS Corp Earnings Call Transcripts
Every quarterly earnings call for GLAUKOS Corp (GKOS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼4.6%
$71.27M
−$27.58M
'22 Q3
22-11-02
▼2.7%
$71.23M
−$31.46M
'22 Q4
23-02-22
▲9.2%
$73.90M
−$34.63M
'23 Q1
23-05-03
▲10.6%
$80.40M
−$32.81M
'23 Q2
23-08-02
▲9.5%
$78.05M
−$30.44M
'23 Q3
23-11-01
▲15.6%
$82.36M
−$36.78M
'23 Q4
24-02-21
▲15.9%
$85.62M
−$40.84M
'24 Q1
24-05-01
▲19%
$95.69M
−$50.55M
'24 Q2
24-07-31
▲23.9%
$96.67M
−$21.41M
'24 Q3
24-11-04
▲28.1%
$105.50M
−$33.58M
'24 Q4
25-02-20
▲24.6%
$106.66M
−$18.15M
'25 Q1
25-05-27
▲29.7%
$124.12M
−$19.66M
'25 Q2
25-07-30
▲38.1%
$133.54M
−$16.23M
'25 Q3
25-10-29
▲35.7%
$143.12M
−$133.66M
'25 Q4
26-02-17
▲41.2%
$150.57M
−$19.78M
'26 Q1
26-04-29
LATEST
▲49.5%
$185.61M
−$18.38M
'26 Q2
26-07-29
Earnings call
FY26 · Q2
2026-07-29
Glaukos' Second Quarter 2026 Financial Results Conference Call
Confident tone
Epioxa (corneal cross-linking) launch
iDose TR (U.S. Glaucoma) growth
iDose re-administration and cannibalization
Revenue
$185.61M
▲ 49.5% YoY Diluted EPS
$-0.31
Gross margin
81.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-16
Truist MedTech Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
William Blair Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-29
GLAUKOS Corp Q1 FY2026 Earnings Call
Confident tone
Epioxa launch and corneal cross-linking
Reimbursement, access, and payer dynamics
iDose TR commercial momentum
Revenue
$150.57M
▲ 41.2% YoY Diluted EPS
$-0.34
Gross margin
77.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-17
GLAUKOS Corp Q4 FY2025 Earnings Call
Confident tone
Photrexa transition to Epioxa
Pipeline and R&D investment
Epioxa launch and keratoconus market development
Revenue
$143.12M*
▲ 35.7% YoY Gross margin
-1.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
GLAUKOS Corp Q3 FY2025 Earnings Call
Confident tone
Epioxa FDA approval and launch
Corneal Health / Photrexa Medicaid rebate impact
iDose TR launch momentum
Revenue
$133.54M
▲ 38.1% YoY Diluted EPS
$-0.28
Gross margin
78.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
GLAUKOS Corp Q2 FY2025 Earnings Call
Confident tone
International Growth & EU Approvals
Capital Allocation / Cash Flow
MIGS / Stent Market Headwinds (MAC LCDs)
Revenue
$124.12M
▲ 29.7% YoY Diluted EPS
$-0.34
Gross margin
78.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-27
GLAUKOS Corp Q1 FY2025 Earnings Call
Confident tone
iDose TR launch and adoption
Interventional glaucoma (IG) category development
Corneal health and Epioxa pipeline
Revenue
$106.66M
▲ 24.6% YoY Diluted EPS
$-0.32
Gross margin
77.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
GLAUKOS Corp Q4 FY2024 Earnings Call
Confident tone
2025 Financial Guidance
Reimbursement and Market Access
iDose TR Commercial Launch
Revenue
$105.50M*
▲ 28.1% YoY Gross margin
72.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-04
GLAUKOS Corp Q3 FY2024 Earnings Call
Confident tone
Reimbursement and J-code Progress
MIGS LCD Coverage and Medicare Advantage
iDose TR Commercial Launch
Revenue
$96.67M
▲ 23.9% YoY Diluted EPS
$-0.39
Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
GLAUKOS Corp Q2 FY2024 Earnings Call
Positive tone
iDose TR Launch
Operating Expenses / Financial Outlook
U.S. Interventional Glaucoma Franchise / iStent
Revenue
$95.69M
▲ 19% YoY Diluted EPS
$-1.00
Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
GLAUKOS Corp Q1 FY2024 Earnings Call
Confident tone
U.S. glaucoma franchise growth
iDose TR launch and commercial rollout
iDose TR reimbursement and market access
Revenue
$85.62M
▲ 15.9% YoY Diluted EPS
$-0.82
Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-21
GLAUKOS Corp Q4 FY2023 Earnings Call
Confident tone
U.S. Glaucoma Franchise / iStent infinite
iDose TR Launch
Pipeline / R&D
Revenue
$82.36M*
▲ 15.6% YoY Gross margin
77.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
GLAUKOS Corp Q3 FY2023 Earnings Call
Revenue
$78.05M
▲ 9.5% YoY Diluted EPS
$-0.63
Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
GLAUKOS Corp Q2 FY2023 Earnings Call
Revenue
$80.40M
▲ 10.6% YoY Diluted EPS
$-0.68
Gross margin
75.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
GLAUKOS Corp Q1 FY2023 Earnings Call
Revenue
$73.90M
▲ 9.2% YoY Diluted EPS
$-0.72
▼ 754.5% YoY Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
GLAUKOS Corp Q4 FY2022 Earnings Call
Revenue
$71.23M
▼ 2.7% YoY Diluted EPS
$-0.66
▼ 240.4% YoY Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
GLAUKOS Corp Q3 FY2022 Earnings Call
Revenue
$71.27M
▼ 4.6% YoY Diluted EPS
$-0.58
▼ 546.2% YoY Gross margin
76.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
GLAUKOS Corp Q2 FY2022 Earnings Call
Revenue
$72.69M
▼ 6.9% YoY Diluted EPS
$-0.96
Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-23
GLAUKOS Corp Q1 FY2022 Earnings Call
Revenue
$67.68M
▼ 0.4% YoY Diluted EPS
$0.11
Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
GLAUKOS Corp Q4 FY2021 Earnings Call
Revenue
$73.24M
▲ 0% YoY Diluted EPS
$0.47
Gross margin
77.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
GLAUKOS Corp Q3 FY2021 Earnings Call
Revenue
$74.71M
▲ 15.2% YoY Diluted EPS
$0.13
Gross margin
79.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
GLAUKOS Corp Q2 FY2021 Earnings Call
Revenue
$78.09M
▲ 147.5% YoY Diluted EPS
$-0.38
Gross margin
77.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
GLAUKOS Corp Q1 FY2021 Earnings Call
Revenue
$67.97M
▲ 22.8% YoY Diluted EPS
$-0.36
Gross margin
75.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
GLAUKOS Corp Q4 FY2020 Earnings Call
Revenue
$73.23M
▲ 11.2% YoY Diluted EPS
$-0.24
▼ 128.6% YoY Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
GLAUKOS Corp Q3 FY2020 Earnings Call
Revenue
$64.83M
▲ 10.8% YoY Diluted EPS
$-0.35
Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
GLAUKOS Corp Q2 FY2020 Earnings Call
Revenue
$31.56M
▼ 46.1% YoY Diluted EPS
$-0.90
Gross margin
31.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
GLAUKOS Corp Q1 FY2020 Earnings Call
Revenue
$55.34M
▲ 2.4% YoY Diluted EPS
$-1.24
Gross margin
41.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
GLAUKOS Corp Q4 FY2019 Earnings Call
Revenue
$65.85M
▲ 21.8% YoY Diluted EPS
$0.84
▲ 2000% YoY Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–30 of 30 earnings calls
Key facts
CIK
1192448
CUSIP
377322102
13F (30d)
336 filings
336 filers
Visit website
Investor relations